Production (Stage)
Satellos Bioscience Inc.
MSCL.TO
TSX
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -40.78% | 34.25% | -50.39% | 14.01% | -6.80% |
| Total Depreciation and Amortization | -88.37% | 290.91% | 0.00% | 10.00% | 33.33% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 223.22% | -116.38% | 752.88% | 330.56% | -107.41% |
| Change in Net Operating Assets | -164.24% | -375.06% | 362.10% | 57.80% | -129.80% |
| Cash from Operations | -32.06% | -73.81% | 22.40% | 25.09% | -198.06% |
| Capital Expenditure | -- | -- | 100.00% | -190.00% | -42.86% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -163.95% | 653.61% | 225.91% | 89.38% |
| Cash from Investing | -- | -163.95% | 654.88% | 225.61% | 89.37% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -100.00% | 19,537.10% | 1,281.25% | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -99.99% | 23,380.80% | 1,284.62% | -- | -- |
| Foreign Exchange rate Adjustments | -98.99% | 845.71% | 615.91% | 103.79% | 89.82% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -130.10% | 145.43% | 515.23% | 65.74% | 57.06% |